Divers pathways mediate delta-opioid receptor down regulation within the same cell.
Various mechanisms have been proposed for opioid receptor down regulation in different experimental preparations. The present study was aimed to test whether distinct mechanisms can mediate opioid receptor down regulation within the same cell. For this purpose we transfected HEK-293 cells with rat delta-opioid receptor (DOR). We exposed the cells to the opioid agonist etorphine in the absence or presence of various pharmacological agents and measured the binding of the opioid ligand [(3)H]diprenorphine to either isolated cell membranes or whole cells. We found that internalization of the receptors into the cell was mediated by clathrin coated pits and that the internalized receptors were degraded either in lysosomes or by proteosomes. Down regulation involved phosphorylation and at least two different kinases, a tyrosine kinase (TK) and MAPK kinase (MEK), mediated DOR down regulation in parallel routes. G-protein-coupled receptor kinase (GRK) was found to have only a minor role in DOR down regulation in HEK-293 cells. On the other hand, in N18TG2 cells that endogenously express delta-opioid receptors, GRK was the predominant kinase mediating DOR down regulation, with only a minor role for TK and MEK. We conclude that down regulation can take place via divers pathways within the same cell, and that in different cells down regulation is mediated by different mechanisms, depending on the kinase profile of the cells and the compartmentalization of the receptors within the cells.
Shapira
M
M
The Mauerberger Chair in Neuropharmacology, Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel-Aviv University, 69978, Tel-Aviv, Israel.
Keren
O
O
Gafni
M
M
Sarne
Y
Y
D000111:Acetylcysteine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D018501:Antirheumatic Agents / Q000494:pharmacology; D002738:Chloroquine / Q000494:pharmacology; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004174:Diprenorphine / Q000378:metabolism / Q000494:pharmacology; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology*; D005048:Etorphine / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000378:metabolism; D019833:Genistein / Q000494:pharmacology; D006801:Humans; D007668:Kidney / Q000166:cytology; D020935:MAP Kinase Signaling System / Q000502:physiology*; D009292:Narcotic Antagonists / Q000378:metabolism / Q000494:pharmacology; D009447:Neuroblastoma; D010766:Phosphorylation; D011869:Radioligand Assay; D017465:Receptors, Opioid, delta / Q000235:genetics / Q000378:metabolism*; D019311:Staurosporine / Q000494:pharmacology; D013722:Teprotide / Q000494:pharmacology; D014162:Transfection; D014316:Tritium; D014407:Tumor Cells, Cultured
D000701:Analgesics, Opioid; D018501:Antirheumatic Agents; D015853:Cysteine Proteinase Inhibitors; D005419:Flavonoids; D009292:Narcotic Antagonists; D017465:Receptors, Opioid, delta; D014316:Tritium; C067713:lactacystin; D004174:Diprenorphine; D005048:Etorphine; D002738:Chloroquine; D013722:Teprotide; D019833:Genistein; D019204:GTP-Binding Proteins; D019311:Staurosporine; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; D000111:Acetylcysteine